This workshop will be delivered in Korean, with English simultaneous interpretation.
Health technology assessment (HTA) is a key tool used by many governments across the world to decide on whether or not a drug will be reimbursed. HTA is also used by the Korean government to make key healthcare decisions. It is one possible way patient organisations can engage with the government to improve access to treatments for their patients, and therefore improve patient outcomes.
In this workshop, we will hear from Sungju Kim, a HTA expert, on:
- How HTA works in Korea, including each step of the end-to-end process
- Where, when and how patient organisations can get involved
We will also hear from fellow patient organisations on their experiences in working with the government to improve access to treatments.
There will also be an opportunity to ask questions at the end of the workshop.
Mr Sungju Kim is an expert advisor for Lee & Ko’s Healthcare Practice Group. Prior to joining Lee & Ko, Mr Kim acquired extensive experience in various areas relating to pharmaceutical products while working for more than 10 years at major pharmaceutical companies (Novartis and Sanofi), where his work included conducting analyses concerning new drug pricing and life-cycle management. He is also credited for carrying out influential price analysis work relating specifically to pharmaceutical products in the broader sphere of the OECD (Organization for Economic Co-operation and Development) countries, as well as conducting a significant price analysis study on the current state of access to new drugs in Korea under the Positive List System (PLS).
Mr Kim’s experience also includes serving as a medical statistician at the Medical Research Collaborating Center of the Seoul National University Hospital, as well as doing clinical statistics and data analysis work for the KCDC (Korea Centers for Disease Control & Prevention).
Drawing upon his extensive experience and special expertise in the areas mentioned above, Mr Kim produces valuable economic assessments and big data analytics relevant to pharmaceutical product pricing issues for various types of clients, including pharmaceutical bio companies, medical institutions and research institutes.
Mr Min Hwan Baek is the Chairman of the Korean Multiple Myeloma Patient Group (KMPG). Mr Baek, with fellow KMPG members have persistently worked to provide prompt access and reimbursement to the new treatments for our patients in Korea.
KMPG's aim is to work together with multiple myeloma patient communities and patients around the world to improve the current treatment environment and provide the latest information on the disease to our patients.